Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) was up 4.1% on Friday . The company traded as high as $9.13 and last traded at $9.10. Approximately 84,320 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 1,162,774 shares. The stock had previously closed at $8.74.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on DNA shares. BTIG Research raised their target price on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a research report on Friday, August 23rd. TD Cowen raised their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, September 20th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $4.58.
View Our Latest Stock Analysis on DNA
Ginkgo Bioworks Price Performance
The firm has a fifty day simple moving average of $8.50. The company has a market capitalization of $579.39 million, a PE ratio of -0.77 and a beta of 1.17.
Institutional Trading of Ginkgo Bioworks
Hedge funds have recently made changes to their positions in the company. Wellington Wealth Strategies LLC. purchased a new position in Ginkgo Bioworks during the second quarter worth about $41,000. PDT Partners LLC acquired a new position in Ginkgo Bioworks during the 3rd quarter worth approximately $1,199,000. Erste Asset Management GmbH purchased a new position in shares of Ginkgo Bioworks during the 3rd quarter worth approximately $4,075,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Ginkgo Bioworks in the 3rd quarter valued at approximately $2,282,000. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Ginkgo Bioworks by 1,606.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company's stock valued at $79,000 after buying an additional 221,078 shares during the period. Institutional investors and hedge funds own 78.63% of the company's stock.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
